## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 3.0% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($238.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Humana price trims gains - Forecast today - 08-12-2025**
- Source: Economies.com | 20251208T130819 | Neutral | Relevance: 99%
-  Humana Inc. (HUM) experienced a pullback after hitting resistance at its 50-day SMA, trimming recent gains despite a strong short-term ascending wave and positive RSI signals. The forecast predicts a rise if the stock stays above $240.00, targeting $298.00. The current price forecast for Humana is neutral.

**2. Humana (NYSE:HUM) Has Announced A Dividend Of $0.885**
- Source: Yahoo Finance | 20251206T040929 | Neutral | Relevance: 99%
-  Humana Inc. (NYSE:HUM) has declared a dividend of $0.885 per share, resulting in a 1.4% dividend yield, with payment scheduled for January 30th. While the company's earnings currently cover the dividend, and EPS is projected to grow, past performance shows a decline in earnings per share. Investors should be mindful of the company's history of pushing the boundaries of sustainability despite having a solid track record of consistent dividend payments.

**3. Humana, Mark Cuban in Talks on Potential Pharmacy Partnership to Simplify Drug Access**
- Source: Digital Health News | 20251206T090345 | Somewhat-Bullish | Relevance: 98%
-  Humana Inc. and billionaire Mark Cuban are discussing a potential pharmacy partnership to streamline drug access and challenge major pharmacy benefit managers (PBMs). The collaboration would involve Humana’s CenterWell pharmacy division and Cuban’s Cost Plus Drugs, focusing on direct-to-employer programs to reduce complexities and offer transparent drug pricing. This initiative highlights a growing industry trend to simplify the drug supply chain and increase transparency amid scrutiny of PBM practices.

**4. Natixis Has $30.88 Million Stock Position in Humana Inc. $HUM**
- Source: MarketBeat | 20251208T122518 | Bullish | Relevance: 98%
- Natixis increased its holdings in Humana Inc. (NYSE:HUM) by 36.8% in Q2, bringing its total to 126,311 shares valued at $30.88 million. This move is part of a broader institutional trend, with other firms like Bank of Nova Scotia and Federated Hermes also significantly boosting their stakes in the insurance provider. Humana continues to receive a "Hold" consensus rating from analysts, with various target price adjustments, and recently declared a quarterly dividend of $0.885.

**5. Humana (NYSE:HUM) Is Paying Out A Dividend Of $0.885**
- Source: Simply Wall Street | 20251206T030847 | Somewhat-Bullish | Relevance: 97%
-  Humana Inc. (NYSE:HUM) is set to pay a dividend of $0.885 per share on January 30th, resulting in a 1.4% yield. The company's earnings easily cover the dividend, with a projected payout ratio of 14% for the next year. Despite past EPS declines, future earnings are predicted to rise, supporting the sustainability of the dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |
| 2025-11-10 | Truist Securiti | $285 | $300 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |
| 2025-11-10 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +2.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.8B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 20.3 |
| Current P/E | 15.0 |
| YoY Growth | -25.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 0.2% to 3.0% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.0pp (needs >3.0% for momentum thesis). MRS_5 at 1.1% confirms short-term momentum alignment. Outperforming sector by 6.4pp, stock-specific strength. Below SMA200 (0.99x), long-term trend not supportive. MACD histogram positive (3.96), confirming momentum. RSI neutral at 54.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 2.97% (CS: 81) | Neutral |
| RSI_14 | 54.3 | Neutral |
| MACD Histogram | 3.96 | Bullish |
| vs SMA20 | 1.066x | Above |
| vs SMA50 | 0.976x | Below |
| vs SMA200 | 0.991x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $256.39
- **Stop Loss:** $238.01 (7.2% risk)
- **Target:** $274.77 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 27
- **Position Value:** $6,922.53
- **Portfolio %:** 6.92%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*